Terms: = Lymphoma AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
247 results:
1. Artemisinin Confers Cytoprotection toward Hydrogen Peroxide-Induced Cell Apoptosis in Retinal Pigment Epithelial Cells in Correlation with the Increased Acetylation of Histone H4 at Lysine 8.
Yang C; Ge L; Yu X; Lazarovici P; Zheng W
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675608
[TBL] [Abstract] [Full Text] [Related]
2. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract] [Full Text] [Related]
3. In Doxorubicin-Adapted Hodgkin lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869.
Casagrande N; Borghese C; Avanzo M; Aldinucci D
Cells; 2023 Nov; 12(23):. PubMed ID: 38067159
[TBL] [Abstract] [Full Text] [Related]
4. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells.
Deng J; Hou B; Hou X; Chen Y; Zhang T; Chen H; Wang Y; Li X
Eur J Med Chem; 2023 Dec; 262():115915. PubMed ID: 37948955
[TBL] [Abstract] [Full Text] [Related]
6. Differential Expression of Proteins Associated with Bipolar Disorder as Identified Using the PeptideShaker Software.
Seregin AA; Smirnova LP; Dmitrieva EM; Zavialova MG; Simutkin GG; Ivanova SA
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894929
[TBL] [Abstract] [Full Text] [Related]
7. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract] [Full Text] [Related]
8. Extracellular vesicles as biomarkers for AIDS-associated non-Hodgkin lymphoma risk.
Martínez LE; Magpantay LI; Guo Y; Hegde P; Detels R; Hussain SK; Epeldegui M
Front Immunol; 2023; 14():1259007. PubMed ID: 37809067
[TBL] [Abstract] [Full Text] [Related]
9. Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma.
Van den Ackerveken P; Lobbens A; Pamart D; Kotronoulas A; Rommelaere G; Eccleston M; Herzog M
Sci Rep; 2023 Sep; 13(1):16335. PubMed ID: 37770512
[TBL] [Abstract] [Full Text] [Related]
10. Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling.
Li W; Sano R; Apatira M; DeAnda F; Gururaja T; Yang M; Lundgaard G; Pan C; Liu J; Zhai Y; Yoon WH; Wang L; Tse C; Souers AJ; Lee CH
Mol Cancer Ther; 2024 Jan; 23(1):35-46. PubMed ID: 37735104
[TBL] [Abstract] [Full Text] [Related]
11. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A; Singh S; Xu-Monette ZY; Coyle KM; Hilton LK; Chavdoula E; Ranganathan P; Jain N; Hanel W; Tsichlis P; Alinari L; Peterson BR; Tao J; Muthusamy N; Baiocchi R; Epperla N; Young KH; Morin R; Sehgal L
Leukemia; 2023 Oct; 37(10):2094-2106. PubMed ID: 37598282
[TBL] [Abstract] [Full Text] [Related]
12. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
Aldana J; Gardner ML; Freitas MA
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
[TBL] [Abstract] [Full Text] [Related]
13. ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to fgfr1 inhibitors through amino acid metabolic reprogramming.
Zhang ZJ; Wu QF; Ren AQ; Chen Q; Shi JZ; Li JP; Liu XY; Zhang ZJ; Tang YZ; Zhao Y; Yao NN; Zhang XY; Liu CP; Dong G; Zhao JX; Xu MJ; Yue YQ; Hu J; Sun F; Liu Y; Ao QL; Zhou FL; Wu H; Zhang TC; Zhu HC
Acta Pharmacol Sin; 2023 Nov; 44(11):2282-2295. PubMed ID: 37280363
[TBL] [Abstract] [Full Text] [Related]
14. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
[TBL] [Abstract] [Full Text] [Related]
15. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract] [Full Text] [Related]
16. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
Kamens JL; Nance S; Koss C; Xu B; Cotton A; Lam JW; Garfinkle EAR; Nallagatla P; Smith AMR; Mitchell S; Ma J; Currier D; Wright WC; Kavdia K; Pagala VR; Kim W; Wallace LM; Cho JH; Fan Y; Seth A; Twarog N; Choi JK; Obeng EA; Hatley ME; Metzger ML; Inaba H; Jeha S; Rubnitz JE; Peng J; Chen T; Shelat AA; Guy RK; Gruber TA
Nat Commun; 2023 Feb; 14(1):809. PubMed ID: 36781850
[TBL] [Abstract] [Full Text] [Related]
17. [In vitro pharmacodynamic studies of novel class Ⅰ and Ⅱb selective histone deacetylase inhibitor purinostat mesylate in the treatment of diffuse large B-cell lymphoma and its mechanism].
Wang J; Zhao AL; Li H; Yang LY; Chen LJ; Niu T
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):753-759. PubMed ID: 36709169
[No Abstract] [Full Text] [Related]
18. Myeloid/lymphoid neoplasm with eosinophilia and BCR/fgfr1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report.
Isaza AP; Quintero SC; González LPQ; Córdoba FEA; Olivar AFA; Ocaña JCB
J Med Case Rep; 2023 Jan; 17(1):39. PubMed ID: 36698221
[TBL] [Abstract] [Full Text] [Related]
19. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y; Nguyen L; Lu CM; Wang E; Lauw MIS; Ball S; Dong N; Moscinski L; Chan O; Yun S; Sallman D; Sokol L; Shah B; Knepper T; Lancet J; Komrokji R; Padron E; Kuykendall A; Zhang L
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e150-e163. PubMed ID: 36624015
[TBL] [Abstract] [Full Text] [Related]
20. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
[TBL] [Abstract] [Full Text] [Related]
[Next]